Formulary-Tailored Pharmacoeconomic Models Being Used By Rx Sales Reps
Executive Summary
Drug company field reps are using custom-tailored models to demonstrate pharmacoeconomic data to formulary committee members, Innovus exec David Thompson said at the pharmacoeconomics conference organized by the Institute for International Research in Philadelphia March 26.
You may also be interested in...
Amgen/Praecis Ask For FDA Meeting After Plenaxis Deemed "Not Approvable"
Amgen and Praecis are requesting a meeting with FDA to discuss issues surrounding the NDA for their prostate cancer treatment Plenaxis (abarelix).
Amgen/Praecis Ask For FDA Meeting After Plenaxis Deemed "Not Approvable"
Amgen and Praecis are requesting a meeting with FDA to discuss issues surrounding the NDA for their prostate cancer treatment Plenaxis (abarelix).
FDA Quality Of Life, Pharmacoeconomic Guidance Development On Hold
FDA development of guidances for including quality of life claims in drug labeling and promotions and for formulary-directed pharmacoeconomic information is on hold until more information is collected.